Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial
Summary We sought to assess the effect of clopidogrel on in-hospital events in unselected patients with acute ST elevation myocardial infarction (STEMI). In a retrospective analysis of consecutive patients enrolled in the Acute Coronary Syndromes (ACOS) registry with acute STEMI we compared outcomes...
Gespeichert in:
| Veröffentlicht in: | Thrombosis and haemostasis 2008-01, Vol.99 (1), p.155-160 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 160 |
|---|---|
| container_issue | 1 |
| container_start_page | 155 |
| container_title | Thrombosis and haemostasis |
| container_volume | 99 |
| creator | Zeymer, Uwe Gitt, Anselm K Jünger, Claus Bauer, Timm Koeth, Oliver Heer, Tobias Mark, Bernd Zahn, Ralf Gottwik, Martin Senges, Jochen |
| description | Summary
We sought to assess the effect of clopidogrel on in-hospital events in unselected patients with acute ST elevation myocardial infarction (STEMI). In a retrospective analysis of consecutive patients enrolled in the Acute Coronary Syndromes (ACOS) registry with acute STEMI we compared outcomes of either adjunctive therapy with aspirin alone or aspirin plus clopidogrel within 24 hours after admission. A total of 7,559 patients were included in this analysis, of whom 3,541 were treated with aspirin alone, and 4,018 with dual antiplatelet therapy. The multivariable analysis with adjustment for baseline characteristics and treatments showed that the rate of in-hospital MACCE (death, non-fatal reinfarction, non-fatal stroke) was significantly lower in the aspirin plus clopidogrel group, compared to the aspirin alone group in the entire cohort and all three reperfusion strategy groups (entire group odds ratio 0.60, 95% CI 0.49–0.72, no reperfusion OR 0.69,95% CI 0.51–0.94,fibrinolysis OR 0.62,95% CI 0.44–0.88, primary PCI OR 0.54, 95% CI 0.39–0.74).There was a significant increase in major bleeding complications with clopidogrel (7.1% vs. 3.4%, p |
| doi_str_mv | 10.1160/TH07-09-0556 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1160_TH07_09_0556</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>18217148</sourcerecordid><originalsourceid>FETCH-LOGICAL-c654t-657b6a9e4e5636b978d3491c125a6eb3ca564d2f4c737871637b74dd557dcd333</originalsourceid><addsrcrecordid>eNq1kb2O1DAURiMEYoeFjhq5oYJAnPgnKdEIWKSVKBgkOuvGvrPxKI4j25nVPg5virMzYiuooLL8-fge-XNRvKTVO0pF9X53Vcmy6sqKc_Go2NRcyFK03Y_HxaZqWFWKmvGL4lmMh6qignX8aXFB25pKytpN8XM7-tkafxNwJHYiYIxN1k8keQJxtiFnAc2iMebjcvA5SzASBwcfiIZgLGgCkyEaA_bBHyHqZYRA8IhTWi-RZYo4ok5oyAzJ3se3Ng0E9JKQfNuRiDcuxyRjR7jXuzt_Gj4-L57sYYz44rxeFt8_fdxtr8rrr5-_bD9cl1pwlkrBZS-gQ4ZcNKLvZGsa1lFNaw4C-0YDF8zUe6ZlI1tJRSN7yYzhXBptmqa5LN6e5urgYwy4V3OwDsKdopVam1Zr06rq1Np0xl-d8HnpHZoH-FxtBl6fgdwIjPsAk7bxges6JlpRZ-7NiUuDRYfq4Jcw5Yf-SatPdNQDpAQLht8j0xC8633MlvwhagB0PiZY99pPae1dQdCDPaKyMS6o4ow6V6wcTEvUwc5Jtbm5bHH_36Li4G_VkNyYffYf-hom_-L6Bb5vFRU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial</title><source>MEDLINE</source><source>Thieme Connect Journals</source><creator>Zeymer, Uwe ; Gitt, Anselm K ; Jünger, Claus ; Bauer, Timm ; Koeth, Oliver ; Heer, Tobias ; Mark, Bernd ; Zahn, Ralf ; Gottwik, Martin ; Senges, Jochen</creator><creatorcontrib>Zeymer, Uwe ; Gitt, Anselm K ; Jünger, Claus ; Bauer, Timm ; Koeth, Oliver ; Heer, Tobias ; Mark, Bernd ; Zahn, Ralf ; Gottwik, Martin ; Senges, Jochen</creatorcontrib><description>Summary
We sought to assess the effect of clopidogrel on in-hospital events in unselected patients with acute ST elevation myocardial infarction (STEMI). In a retrospective analysis of consecutive patients enrolled in the Acute Coronary Syndromes (ACOS) registry with acute STEMI we compared outcomes of either adjunctive therapy with aspirin alone or aspirin plus clopidogrel within 24 hours after admission. A total of 7,559 patients were included in this analysis, of whom 3,541 were treated with aspirin alone, and 4,018 with dual antiplatelet therapy. The multivariable analysis with adjustment for baseline characteristics and treatments showed that the rate of in-hospital MACCE (death, non-fatal reinfarction, non-fatal stroke) was significantly lower in the aspirin plus clopidogrel group, compared to the aspirin alone group in the entire cohort and all three reperfusion strategy groups (entire group odds ratio 0.60, 95% CI 0.49–0.72, no reperfusion OR 0.69,95% CI 0.51–0.94,fibrinolysis OR 0.62,95% CI 0.44–0.88, primary PCI OR 0.54, 95% CI 0.39–0.74).There was a significant increase in major bleeding complications with clopidogrel (7.1% vs. 3.4%, p<0.001). In clinical practice early adjunctive therapy with clopidogrel in addition to aspirin in patients with STEMI is associated with a significant reduction of in-hospital MACCE regardless of the initial reperfusion strategy. This advantage was associated with an increase in major bleeding complications.</description><identifier>ISSN: 0340-6245</identifier><identifier>EISSN: 2567-689X</identifier><identifier>DOI: 10.1160/TH07-09-0556</identifier><identifier>PMID: 18217148</identifier><identifier>CODEN: THHADQ</identifier><language>eng</language><publisher>Stuttgart: Schattauer Verlag für Medizin und Naturwissenschaften</publisher><subject>Aged ; Aged, 80 and over ; Angioplasty, Balloon, Coronary - adverse effects ; Aspirin - adverse effects ; Aspirin - therapeutic use ; Biological and medical sciences ; Blood coagulation. Blood cells ; Cardiovascular Biology and Cell Signalling ; Cerebrovascular Disorders - etiology ; Cerebrovascular Disorders - mortality ; Cerebrovascular Disorders - prevention & control ; clinical practice ; clopidogrel ; Drug Therapy, Combination ; Female ; Fundamental and applied biological sciences. Psychology ; Heart Diseases - etiology ; Heart Diseases - mortality ; Heart Diseases - prevention & control ; Hematologic and hematopoietic diseases ; Hemorrhage - chemically induced ; Hospital Mortality ; Hospitalization ; Humans ; Male ; Medical sciences ; Middle Aged ; Molecular and cellular biology ; Myocardial Infarction - complications ; Myocardial Infarction - drug therapy ; Myocardial Infarction - mortality ; Myocardial Infarction - therapy ; Odds Ratio ; Platelet Aggregation Inhibitors - adverse effects ; Platelet Aggregation Inhibitors - therapeutic use ; Platelet diseases and coagulopathies ; primary percutaneous coronary intervention ; Prognosis ; reperfusion therapy ; Research Design ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Secondary Prevention ; ST elevation myocardial infarction ; Stroke - prevention & control ; Thrombolytic Therapy - adverse effects ; Ticlopidine - adverse effects ; Ticlopidine - analogs & derivatives ; Ticlopidine - therapeutic use ; Time Factors ; Treatment Outcome</subject><ispartof>Thrombosis and haemostasis, 2008-01, Vol.99 (1), p.155-160</ispartof><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c654t-657b6a9e4e5636b978d3491c125a6eb3ca564d2f4c737871637b74dd557dcd333</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.thieme-connect.de/products/ejournals/pdf/10.1160/TH07-09-0556.pdf$$EPDF$$P50$$Gthieme$$H</linktopdf><linktohtml>$$Uhttps://www.thieme-connect.de/products/ejournals/html/10.1160/TH07-09-0556$$EHTML$$P50$$Gthieme$$H</linktohtml><link.rule.ids>314,776,780,3005,4010,27900,27901,27902,54534,54535</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19946862$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18217148$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zeymer, Uwe</creatorcontrib><creatorcontrib>Gitt, Anselm K</creatorcontrib><creatorcontrib>Jünger, Claus</creatorcontrib><creatorcontrib>Bauer, Timm</creatorcontrib><creatorcontrib>Koeth, Oliver</creatorcontrib><creatorcontrib>Heer, Tobias</creatorcontrib><creatorcontrib>Mark, Bernd</creatorcontrib><creatorcontrib>Zahn, Ralf</creatorcontrib><creatorcontrib>Gottwik, Martin</creatorcontrib><creatorcontrib>Senges, Jochen</creatorcontrib><title>Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial</title><title>Thrombosis and haemostasis</title><addtitle>Thromb Haemost</addtitle><description>Summary
We sought to assess the effect of clopidogrel on in-hospital events in unselected patients with acute ST elevation myocardial infarction (STEMI). In a retrospective analysis of consecutive patients enrolled in the Acute Coronary Syndromes (ACOS) registry with acute STEMI we compared outcomes of either adjunctive therapy with aspirin alone or aspirin plus clopidogrel within 24 hours after admission. A total of 7,559 patients were included in this analysis, of whom 3,541 were treated with aspirin alone, and 4,018 with dual antiplatelet therapy. The multivariable analysis with adjustment for baseline characteristics and treatments showed that the rate of in-hospital MACCE (death, non-fatal reinfarction, non-fatal stroke) was significantly lower in the aspirin plus clopidogrel group, compared to the aspirin alone group in the entire cohort and all three reperfusion strategy groups (entire group odds ratio 0.60, 95% CI 0.49–0.72, no reperfusion OR 0.69,95% CI 0.51–0.94,fibrinolysis OR 0.62,95% CI 0.44–0.88, primary PCI OR 0.54, 95% CI 0.39–0.74).There was a significant increase in major bleeding complications with clopidogrel (7.1% vs. 3.4%, p<0.001). In clinical practice early adjunctive therapy with clopidogrel in addition to aspirin in patients with STEMI is associated with a significant reduction of in-hospital MACCE regardless of the initial reperfusion strategy. This advantage was associated with an increase in major bleeding complications.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Angioplasty, Balloon, Coronary - adverse effects</subject><subject>Aspirin - adverse effects</subject><subject>Aspirin - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood coagulation. Blood cells</subject><subject>Cardiovascular Biology and Cell Signalling</subject><subject>Cerebrovascular Disorders - etiology</subject><subject>Cerebrovascular Disorders - mortality</subject><subject>Cerebrovascular Disorders - prevention & control</subject><subject>clinical practice</subject><subject>clopidogrel</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Heart Diseases - etiology</subject><subject>Heart Diseases - mortality</subject><subject>Heart Diseases - prevention & control</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hemorrhage - chemically induced</subject><subject>Hospital Mortality</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Molecular and cellular biology</subject><subject>Myocardial Infarction - complications</subject><subject>Myocardial Infarction - drug therapy</subject><subject>Myocardial Infarction - mortality</subject><subject>Myocardial Infarction - therapy</subject><subject>Odds Ratio</subject><subject>Platelet Aggregation Inhibitors - adverse effects</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Platelet diseases and coagulopathies</subject><subject>primary percutaneous coronary intervention</subject><subject>Prognosis</subject><subject>reperfusion therapy</subject><subject>Research Design</subject><subject>Retrospective Studies</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Secondary Prevention</subject><subject>ST elevation myocardial infarction</subject><subject>Stroke - prevention & control</subject><subject>Thrombolytic Therapy - adverse effects</subject><subject>Ticlopidine - adverse effects</subject><subject>Ticlopidine - analogs & derivatives</subject><subject>Ticlopidine - therapeutic use</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>0340-6245</issn><issn>2567-689X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNq1kb2O1DAURiMEYoeFjhq5oYJAnPgnKdEIWKSVKBgkOuvGvrPxKI4j25nVPg5virMzYiuooLL8-fge-XNRvKTVO0pF9X53Vcmy6sqKc_Go2NRcyFK03Y_HxaZqWFWKmvGL4lmMh6qignX8aXFB25pKytpN8XM7-tkafxNwJHYiYIxN1k8keQJxtiFnAc2iMebjcvA5SzASBwcfiIZgLGgCkyEaA_bBHyHqZYRA8IhTWi-RZYo4ok5oyAzJ3se3Ng0E9JKQfNuRiDcuxyRjR7jXuzt_Gj4-L57sYYz44rxeFt8_fdxtr8rrr5-_bD9cl1pwlkrBZS-gQ4ZcNKLvZGsa1lFNaw4C-0YDF8zUe6ZlI1tJRSN7yYzhXBptmqa5LN6e5urgYwy4V3OwDsKdopVam1Zr06rq1Np0xl-d8HnpHZoH-FxtBl6fgdwIjPsAk7bxges6JlpRZ-7NiUuDRYfq4Jcw5Yf-SatPdNQDpAQLht8j0xC8633MlvwhagB0PiZY99pPae1dQdCDPaKyMS6o4ow6V6wcTEvUwc5Jtbm5bHH_36Li4G_VkNyYffYf-hom_-L6Bb5vFRU</recordid><startdate>200801</startdate><enddate>200801</enddate><creator>Zeymer, Uwe</creator><creator>Gitt, Anselm K</creator><creator>Jünger, Claus</creator><creator>Bauer, Timm</creator><creator>Koeth, Oliver</creator><creator>Heer, Tobias</creator><creator>Mark, Bernd</creator><creator>Zahn, Ralf</creator><creator>Gottwik, Martin</creator><creator>Senges, Jochen</creator><general>Schattauer Verlag für Medizin und Naturwissenschaften</general><general>Schattauer GmbH</general><general>Schattauer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>200801</creationdate><title>Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial</title><author>Zeymer, Uwe ; Gitt, Anselm K ; Jünger, Claus ; Bauer, Timm ; Koeth, Oliver ; Heer, Tobias ; Mark, Bernd ; Zahn, Ralf ; Gottwik, Martin ; Senges, Jochen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c654t-657b6a9e4e5636b978d3491c125a6eb3ca564d2f4c737871637b74dd557dcd333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Angioplasty, Balloon, Coronary - adverse effects</topic><topic>Aspirin - adverse effects</topic><topic>Aspirin - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood coagulation. Blood cells</topic><topic>Cardiovascular Biology and Cell Signalling</topic><topic>Cerebrovascular Disorders - etiology</topic><topic>Cerebrovascular Disorders - mortality</topic><topic>Cerebrovascular Disorders - prevention & control</topic><topic>clinical practice</topic><topic>clopidogrel</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Heart Diseases - etiology</topic><topic>Heart Diseases - mortality</topic><topic>Heart Diseases - prevention & control</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hemorrhage - chemically induced</topic><topic>Hospital Mortality</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Molecular and cellular biology</topic><topic>Myocardial Infarction - complications</topic><topic>Myocardial Infarction - drug therapy</topic><topic>Myocardial Infarction - mortality</topic><topic>Myocardial Infarction - therapy</topic><topic>Odds Ratio</topic><topic>Platelet Aggregation Inhibitors - adverse effects</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Platelet diseases and coagulopathies</topic><topic>primary percutaneous coronary intervention</topic><topic>Prognosis</topic><topic>reperfusion therapy</topic><topic>Research Design</topic><topic>Retrospective Studies</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Secondary Prevention</topic><topic>ST elevation myocardial infarction</topic><topic>Stroke - prevention & control</topic><topic>Thrombolytic Therapy - adverse effects</topic><topic>Ticlopidine - adverse effects</topic><topic>Ticlopidine - analogs & derivatives</topic><topic>Ticlopidine - therapeutic use</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zeymer, Uwe</creatorcontrib><creatorcontrib>Gitt, Anselm K</creatorcontrib><creatorcontrib>Jünger, Claus</creatorcontrib><creatorcontrib>Bauer, Timm</creatorcontrib><creatorcontrib>Koeth, Oliver</creatorcontrib><creatorcontrib>Heer, Tobias</creatorcontrib><creatorcontrib>Mark, Bernd</creatorcontrib><creatorcontrib>Zahn, Ralf</creatorcontrib><creatorcontrib>Gottwik, Martin</creatorcontrib><creatorcontrib>Senges, Jochen</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Thrombosis and haemostasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zeymer, Uwe</au><au>Gitt, Anselm K</au><au>Jünger, Claus</au><au>Bauer, Timm</au><au>Koeth, Oliver</au><au>Heer, Tobias</au><au>Mark, Bernd</au><au>Zahn, Ralf</au><au>Gottwik, Martin</au><au>Senges, Jochen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial</atitle><jtitle>Thrombosis and haemostasis</jtitle><addtitle>Thromb Haemost</addtitle><date>2008-01</date><risdate>2008</risdate><volume>99</volume><issue>1</issue><spage>155</spage><epage>160</epage><pages>155-160</pages><issn>0340-6245</issn><eissn>2567-689X</eissn><coden>THHADQ</coden><abstract>Summary
We sought to assess the effect of clopidogrel on in-hospital events in unselected patients with acute ST elevation myocardial infarction (STEMI). In a retrospective analysis of consecutive patients enrolled in the Acute Coronary Syndromes (ACOS) registry with acute STEMI we compared outcomes of either adjunctive therapy with aspirin alone or aspirin plus clopidogrel within 24 hours after admission. A total of 7,559 patients were included in this analysis, of whom 3,541 were treated with aspirin alone, and 4,018 with dual antiplatelet therapy. The multivariable analysis with adjustment for baseline characteristics and treatments showed that the rate of in-hospital MACCE (death, non-fatal reinfarction, non-fatal stroke) was significantly lower in the aspirin plus clopidogrel group, compared to the aspirin alone group in the entire cohort and all three reperfusion strategy groups (entire group odds ratio 0.60, 95% CI 0.49–0.72, no reperfusion OR 0.69,95% CI 0.51–0.94,fibrinolysis OR 0.62,95% CI 0.44–0.88, primary PCI OR 0.54, 95% CI 0.39–0.74).There was a significant increase in major bleeding complications with clopidogrel (7.1% vs. 3.4%, p<0.001). In clinical practice early adjunctive therapy with clopidogrel in addition to aspirin in patients with STEMI is associated with a significant reduction of in-hospital MACCE regardless of the initial reperfusion strategy. This advantage was associated with an increase in major bleeding complications.</abstract><cop>Stuttgart</cop><pub>Schattauer Verlag für Medizin und Naturwissenschaften</pub><pmid>18217148</pmid><doi>10.1160/TH07-09-0556</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-6245 |
| ispartof | Thrombosis and haemostasis, 2008-01, Vol.99 (1), p.155-160 |
| issn | 0340-6245 2567-689X |
| language | eng |
| recordid | cdi_crossref_primary_10_1160_TH07_09_0556 |
| source | MEDLINE; Thieme Connect Journals |
| subjects | Aged Aged, 80 and over Angioplasty, Balloon, Coronary - adverse effects Aspirin - adverse effects Aspirin - therapeutic use Biological and medical sciences Blood coagulation. Blood cells Cardiovascular Biology and Cell Signalling Cerebrovascular Disorders - etiology Cerebrovascular Disorders - mortality Cerebrovascular Disorders - prevention & control clinical practice clopidogrel Drug Therapy, Combination Female Fundamental and applied biological sciences. Psychology Heart Diseases - etiology Heart Diseases - mortality Heart Diseases - prevention & control Hematologic and hematopoietic diseases Hemorrhage - chemically induced Hospital Mortality Hospitalization Humans Male Medical sciences Middle Aged Molecular and cellular biology Myocardial Infarction - complications Myocardial Infarction - drug therapy Myocardial Infarction - mortality Myocardial Infarction - therapy Odds Ratio Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - therapeutic use Platelet diseases and coagulopathies primary percutaneous coronary intervention Prognosis reperfusion therapy Research Design Retrospective Studies Risk Assessment Risk Factors Secondary Prevention ST elevation myocardial infarction Stroke - prevention & control Thrombolytic Therapy - adverse effects Ticlopidine - adverse effects Ticlopidine - analogs & derivatives Ticlopidine - therapeutic use Time Factors Treatment Outcome |
| title | Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T13%3A17%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clopidogrel%20in%20addition%20to%20aspirin%20reduces%20in-hospital%20major%20cardiac%20and%20cerebrovascular%20events%20in%20unselected%20patients%20with%20acute%20ST%20segment%20elevation%20myocardial&rft.jtitle=Thrombosis%20and%20haemostasis&rft.au=Zeymer,%20Uwe&rft.date=2008-01&rft.volume=99&rft.issue=1&rft.spage=155&rft.epage=160&rft.pages=155-160&rft.issn=0340-6245&rft.eissn=2567-689X&rft.coden=THHADQ&rft_id=info:doi/10.1160/TH07-09-0556&rft_dat=%3Cpubmed_cross%3E18217148%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/18217148&rfr_iscdi=true |